Status:
COMPLETED
Carbetocin at Elective Cesarean Delivery
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions:
Postpartum Hemorrhage
Eligibility:
FEMALE
18-50 years
Phase:
NA
Brief Summary
Post-partum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the most commonly uterotonic drug used to prevent and treat PPH in North America, however, there are some limitat...
Detailed Description
The Society of Obstetricians and Gynecologists of Canada (SOGC)recently recommended a 100mcg intravenous bolus dose of carbetocin following Cesarean delivery. However, a dose response study to determi...
Eligibility Criteria
Inclusion
- All patients planned for elective cesarean delivery under spinal anesthesia;
- All patients who gave written informed consent to participate in this study.
Exclusion
- All patients who refuse to give written informed consent.
- All patients who claim allergy or hypersensitivity to carbetocin or oxytocin.
- All patients with conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis.
- All patients with hepatic, renal, and vascular disease,
- All patients requiring general anesthesia prior to the administration of the study drug.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01262742
Start Date
November 1 2010
End Date
March 1 2011
Last Update
April 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G1X5